脑内微小RNA基因治疗在亨廷顿病小型猪中实现广泛持续靶点结合
研究评估了经MRI引导对流增强递送的重组AAV5载体表达靶向人HTT的microRNA(rAAV5-miHTT)在转基因亨廷顿病小型猪中的可转化性和长期耐久性。每脑注射1.2×10^13个载体基因组拷贝后,载体DNA广泛分布,注射区突变HTT蛋白降低超过75%,远端区域降低30%至50%,脑脊液突变HTT蛋白在6和12个月时降低25%至30%。
要点
- rAAV5-miHTT经MRI引导对流增强递送可在大型脑内广泛分布并持续表达至少12个月
- 注射区突变HTT蛋白降低超过75%,远端区域降低30%至50%
- 脑脊液miHTT表达和突变HTT蛋白降低可反映脑内载体表达与疗效
核心结论
- rAAV5-miHTT在亨廷顿病小型猪脑内实现广泛分布、强效且持久的靶点结合,脑脊液分析有潜力用于临床确定载体表达和疗效。
研究设计与样本
- 在转基因亨廷顿病小型猪中,经MRI引导对流增强递送rAAV5-miHTT(每脑1.2×10^13个载体基因组拷贝)至双侧尾状核和壳核,以年龄匹配的未治疗动物为对照。
主要发现
- 载体DNA在脑内广泛分布,最高浓度位于靶区(纹状体)、丘脑和皮质区域。
- 给药后6个月和12个月时载体DNA存在和转基因表达相似。
- miHTT表达与载体DNA强相关,注射区突变HTT蛋白降低超过75%,远端区域降低30%至50%。
- 脑脊液miHTT表达检测至12个月,脑脊液突变HTT蛋白在给药后6和12个月降低25%至30%。
临床怎么用
- 支持在亨廷顿病临床研究中进一步评估rAAV5-miHTT经MRI引导对流增强递送的安全性和有效性。
- 脑脊液miHTT表达和突变HTT蛋白水平可作为临床监测载体表达和疗效的转化生物标志物。
局限性
- 研究在转基因亨廷顿病小型猪中进行,结果向人类患者的转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Huntingtin (HTT)-lowering therapies hold promise to slow down neurodegeneration in Huntington's disease (HD). Here, we assessed the translatability and long-term durability of recombinant adeno-associated viral vector serotype 5 expressing a microRNA targeting human HTT (rAAV5-miHTT) administered by magnetic resonance imaging-guided convention-enhanced delivery in transgenic HD minipigs. rAAV5-miHTT (1.2 × 1013 vector genome (VG) copies per brain) was successfully administered into the striatum (bilaterally in caudate and putamen), using age-matched untreated animals as controls. Widespread brain biodistribution of vector DNA was observed, with the highest concentration in target (striatal) regions, thalamus, and cortical regions. Vector DNA presence and transgene expression were similar at 6 and 12 months after administration. Expression of miHTT strongly correlated with vector DNA, with a corresponding reduction of mutant HTT (mHTT) protein of more than 75% in injected areas, and 30 to 50% lowering in distal regions. Translational pharmacokinetic and pharmacodynamic measures in cerebrospinal fluid (CSF) were largely in line with the effects observed in the brain. CSF miHTT expression was detected up to 12 months, with CSF mHTT protein lowering of 25 to 30% at 6 and 12 months after dosing. This study demonstrates widespread biodistribution, strong and durable efficiency of rAAV5-miHTT in disease-relevant regions in a large brain, and the potential of using CSF analysis to determine vector expression and efficacy in the clinic.
引用
- Vallès A, Evers MM, Stam A, et al. Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy. Sci Transl Med. 2021. PMID: 33827977. doi:10.1126/scitranslmed.abb8920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。